Evidence
A meta-analysis of 106 prospective studies of implants with the TiUnite® surface reported 10-year survival of 95.1% at implant level and 91.5% at patient level. 1
Peri-implantitis was reported by only 19 of the studies (5.2% of patients in those studies). One author has been involved in research on this surface family for decades; see the paper for conflict-of-interest statements.
In an animal study (minipigs) with grafted bone defects, the anodised gradient surface and two sandblasted, acid-etched comparison surfaces showed no difference in the amount and height of new bone at 2 and 8 weeks. 4
Animal study with short healing times; results cannot be transferred directly to patients.
Which one is right for me?
Neither is "better" in general. A design difference is not evidence that one gives better results for you. The surgeon decides based on your bone, the site and the planned teeth.
Would you like a clinician to explain which options fit your situation?
Request an assessmentLast updated 28 Sep 2026 · How we review
Sources
- Systematic reviewKarl M, Albrektsson T. Clinical performance of implants with a moderately rough (TiUnite) surface: meta-analysis of prospective studies. Int J Oral Maxillofac Implants 2017 — Int J Oral Maxillofac Implants, 2017. Accessed 28 Sep 2026.
- Regulatory recordFDA 510(k) K202344 — TiUltra Implants and Xeal Abutments (Nobel Biocare) — U.S. Food and Drug Administration, 2020-11-16. Accessed 28 Sep 2026.
- Regulatory recordFDA 510(k) K050705 — TiUnite Implants — U.S. Food and Drug Administration, 2005-05-19. Accessed 28 Sep 2026.
- Preclinical studyShahdad S et al. Osseointegration of anodized vs sandblasted implant surfaces in a grafted dehiscence defect: minipig model. Clin Oral Implants Res 2025 — Clin Oral Implants Res, 2025. Accessed 28 Sep 2026.
- Regulatory recordFDA 510(k) K211109 — N1 TiUltra TCC Implant System (Nobel Biocare) — U.S. Food and Drug Administration, 2021-12-21. Accessed 28 Sep 2026.
- Regulatory recordFDA 510(k) K252197 — Nobel Biocare S Series Implants (510(k) summary) — U.S. Food and Drug Administration, 2026-02-18. Accessed 28 Sep 2026.
- Regulatory recordFDA 510(k) K243834 — NobelZygoma TiUltra Implant system — U.S. Food and Drug Administration, 2025-08-25. Accessed 28 Sep 2026.
- Manufacturer documentationNobel Biocare — CC implants and prosthetics product overview 25.1 (95092) — Nobel Biocare Services AG, 2025. Accessed 28 Sep 2026.
